Workflow
Autobio(603658)
icon
Search documents
郑州安图生物工程股份有限公司关于公司及全资子公司获得医疗器械注册证的公告
■ 证券代码:603658 证券简称:安图生物 公告编号:2025-065 郑州安图生物工程股份有限公司 关于公司及全资子公司获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司(以下简称"公司"或"安图生物")及全资子公司安图实验仪器(郑州) 有限公司(以下简称"安图仪器")于近日收到国家药品监督管理局、河南省药品监督管理局颁发的医疗 器械注册证,具体如下: 一、医疗器械注册证的具体情况 二、同类产品相关情况 根据国家药品监督管理局官网数据查询信息,截至公告日,国内外同行业部分厂家已取得上述部分类似 产品的医疗器械注册证。详情请登录国家药品监督管理局(https://www.nmpa.gov.cn)查阅。 三、对公司的影响 四、风险提示 上述产品上市后实际销售情况取决于未来市场的推广效果,目前尚无法预测上述产品对公司未来营业收 入的影响,敬请投资者注意投资风险。 特此公告。 郑州安图生物工程股份有限公司董事会 2025年9月29日 上述医疗器械注册证的取得进一步丰富了公司产品 ...
安图生物及全资子公司获得医疗器械注册证
Zhi Tong Cai Jing· 2025-09-29 13:33
上述医疗器械注册证的取得进一步丰富了公司产品菜单,不断满足市场需求,是对公司现有检测产品的 有效补充,可以逐步提高公司产品的整体竞争力,短期内对公司的经营业绩影响较小。 安图生物(603658)(603658.SH)发布公告,公司及全资子公司安图实验仪器(郑州)有限公司(简称"安图 仪器")于近日收到国家药品监督管理局、河南省药品监督管理局颁发的医疗器械注册证。 ...
安图生物(603658.SH)及全资子公司获得医疗器械注册证
智通财经网· 2025-09-29 09:37
上述医疗器械注册证的取得进一步丰富了公司产品菜单,不断满足市场需求,是对公司现有检测产品的 有效补充,可以逐步提高公司产品的整体竞争力,短期内对公司的经营业绩影响较小。 安图生物(603658.SH)发布公告,公司及全资子公司安图实验仪器(郑州)有限公司(简称"安图仪器")于近 日收到国家药品监督管理局、河南省药品监督管理局颁发的医疗器械注册证。 ...
安图生物(603658) - 安图生物关于公司及全资子公司获得医疗器械注册证的公告
2025-09-29 09:00
二、同类产品相关情况 证券代码:603658 证券简称:安图生物 公告编号:2025-065 郑州安图生物工程股份有限公司 关于公司及全资子公司获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司(以下简称"公司"或"安图生物")及全 资子公司安图实验仪器(郑州)有限公司(以下简称"安图仪器")于近日收到 国家药品监督管理局、河南省药品监督管理局颁发的医疗器械注册证,具体如下: | 编号 | 产品名称 | 注册证编号 | 注册证 | 预期用途 | 所属 | | --- | --- | --- | --- | --- | --- | | | | | 有效期 | | 公司 | | 1 | 曲霉菌半乳甘露聚糖 抗原检测试剂盒(磁 微粒化学发光法) | 国械注准 20253401899 | 年 5 | 本产品用于体外定性检测人血清中的 曲霉菌半乳甘露聚糖抗原(GM)。 | | | 2 | 曲霉菌 抗体检测 IgG 试剂盒(磁微粒化学 发光法) | 国械注准 20253402004 | ...
安图生物(603658) - 安图生物关于使用闲置募集资金进行现金管理赎回及进展的公告
2025-09-26 09:30
基本情况 | 投资金额 | 万元 17,000 | | --- | --- | | 投资种类 | 大额存单 | | 资金来源 | 募集资金 | 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理 赎回及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 证券代码:603658 证券简称:安图生物 公告编号:2025-064 已履行的审议程序 郑州安图生物工程股份有限公司(以下简称"公司")于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次会议,审议 通过《关于使用部分闲置募集资金进行现金管理的议案》,同意公司在 确保不影响募集资金投资项目建设和募集资金使用的情况下,公司拟分 别使用不超过 1.7 亿元公开发行可转换公司债券闲置募集资金和不超过 17 亿元非公开发行股票闲置募集资金进行现金管理,分别用于购买单次 持有期限不超过 12 个月的结构性存款、大额存单、国债逆回购、券商收 益凭证、券商理财产品等安全性高、流动性好的保本型产品。在上述额 度范围内,资金可在 ...
安图生物9月22日获融资买入1056.65万元,融资余额6.20亿元
Xin Lang Zheng Quan· 2025-09-23 01:23
截至6月30日,安图生物股东户数3.42万,较上期增加0.04%;人均流通股16719股,较上期减少0.04%。 2025年1月-6月,安图生物实现营业收入20.60亿元,同比减少6.65%;归母净利润5.71亿元,同比减少 7.83%。 9月22日,安图生物跌0.94%,成交额1.01亿元。两融数据显示,当日安图生物获融资买入额1056.65万 元,融资偿还666.94万元,融资净买入389.71万元。截至9月22日,安图生物融资融券余额合计6.22亿 元。 融资方面,安图生物当日融资买入1056.65万元。当前融资余额6.20亿元,占流通市值的2.72%,融资余 额低于近一年50%分位水平,处于较低位。 融券方面,安图生物9月22日融券偿还100.00股,融券卖出0.00股,按当日收盘价计算,卖出金额0.00 元;融券余量4.55万股,融券余额181.36万元,低于近一年10%分位水平,处于低位。 资料显示,郑州安图生物工程股份有限公司位于河南省郑州经济技术开发区经开第十五大街199号,成 立日期1999年9月15日,上市日期2016年9月1日,公司主营业务涉及体外诊断试剂及仪器的研发、生产 和销售。主营 ...
安图生物:亚太地区以化学发光产品销售为主,欧洲高端市场以微生物质谱检测为“敲门砖”
Cai Jing Wang· 2025-09-22 11:04
Core Insights - Antu Biotech held a performance briefing for the first half of 2025, highlighting significant growth in overseas markets [1] Overseas Business Performance - The company has successfully sold products to over 100 countries and regions globally, with a focus on Asia, Europe, the Middle East, Africa, and Latin America [1] - Key products for international promotion include chemiluminescence, mass spectrometry, and immunoassay systems, with rapid growth observed in Asia (India, Southeast Asia), Latin America, and Europe [1] - The Asia-Pacific region primarily drives sales through chemiluminescence products, while Europe focuses on mass spectrometry products [1] Market Contribution - Overseas sales from the Asian market contribute over 40% to the company's revenue and continue to grow rapidly [1] - The contribution from emerging markets in Latin America is increasing year by year [1] - In Europe, the high-end market is gradually increasing its market share using mass spectrometry as an entry point [1]
安图生物(603658):国内发光业务承压,Q2环比改善
Huachuang Securities· 2025-09-15 09:41
Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 51 yuan [2][8]. Core Views - The company's revenue for the first half of 2025 was 2.06 billion yuan, a decrease of 6.65% year-on-year, while the net profit attributable to the parent company was 571 million yuan, down 7.83% [2]. - In Q2 2025, the company achieved revenue of 1.064 billion yuan, a decline of 4.79%, but the net profit attributable to the parent company increased by 1.97% to 301 million yuan, indicating a quarter-on-quarter improvement [2]. - The domestic luminous business is under pressure, but there was a sequential improvement in Q2 [2][8]. - The company continues to focus on R&D, with an investment of 350 million yuan in the first half of 2025, accounting for 16.99% of revenue [8]. Financial Summary - For 2025, the company is projected to achieve total revenue of 4.658 billion yuan, with a year-on-year growth rate of 4.2% [4]. - The net profit attributable to the parent company is expected to be 1.264 billion yuan in 2025, reflecting a growth rate of 5.8% [4]. - The earnings per share (EPS) for 2025 is estimated at 2.21 yuan, with a price-to-earnings (P/E) ratio of 19 times [4]. - The company’s total assets are projected to reach 12.306 billion yuan by 2025, with a debt-to-equity ratio of 9.9% [9]. Business Performance - Domestic revenue in the first half of 2025 was 1.904 billion yuan, down 8.32%, while overseas revenue increased by 19.78% to 157 million yuan [8]. - The company has accelerated its global expansion, entering over 100 countries and regions, and has established subsidiaries in Hong Kong, Hungary, and Indonesia to enhance local operations [8]. - The company has launched several innovative products, including a series of gene sequencers and an AI-assisted clinical decision-making system [8].
又20起合作达成!医疗器械BD月报首发
思宇MedTech· 2025-09-14 01:08
Core Viewpoint - The article discusses the evolving landscape of the medical device industry in China, highlighting the importance of business development (BD) strategies that go beyond mere numbers to encompass strategic partnerships, market expansion, and technological integration [1][24]. Group 1: Key Trends in Medical Device BD - The primary keywords for the period from July to September include cross-border introduction and global distribution, strategic cooperation, and capital and cross-industry integration [2]. - Companies are accelerating market expansion and ecosystem building through transactions across various fields, including cardiovascular, neuro-intervention, ophthalmology, IVD, and critical care [3]. Group 2: Representative Events - A total of 20 significant events were summarized, showcasing a "multi-line advancement" scenario in the industry [4]. - Notable collaborations include: - Nanjing Jianxin Medical and Heqi Family Office focusing on medical device R&D and wealth management [6]. - Olympus and Xingchenhai Medical signing a global distribution agreement for disposable urology products [6]. - He’s Eye Group and Zeiss China Medical forming a strategic partnership to enhance ophthalmic surgical technology [6]. Group 3: Cross-Border and Global Distribution - Cross-border transactions remain a hot topic, with domestic companies leveraging global markets for growth while foreign giants introduce Chinese innovations [9]. - The partnership between Ruichao Dinkai Group and Beijing Amite focuses on vascular intervention products, marking a new phase in safety standards [7]. Group 4: Strategic Cooperation and Channel Expansion - Strategic cooperation is increasingly focused on building ecosystems rather than single product breakthroughs, with companies forming partnerships in fields like ophthalmology, IVD, and diagnostics [19]. - The collaboration between Wanfu Biological and Beiden Medical aims to match products with non-public medical channels effectively [15]. Group 5: Capital Support and Cross-Industry Integration - Capital is becoming an invisible driver of medical device BD, with partnerships exploring new models for medical device distribution [20]. - The collaboration between Beijing Huamai Supply Chain Management and Hongyi Consulting aims to create a one-stop service for medical device distribution [20]. Group 6: Smart Hospitals and Full-Chain Coordination - The focus on smart hospitals and full-chain coordination is becoming a priority for large enterprises, integrating supply chains, academic promotion, and clinical needs [23]. - Collaborations like that of Ruibo Zehou Technology and China National Pharmaceutical Group aim to develop automated systems for smart hospitals [21]. Conclusion - The medical device industry in China is transitioning from a "single product-driven" phase to a more diversified approach supported by capital, channels, and ecosystems, indicating a long-term growth trajectory [24].
安图生物(603658) - 安图生物关于召开2025年半年度业绩说明会的公告
2025-09-12 09:00
证券代码:603658 证券简称:安图生物 公告编号:2025-063 投资者可于 2025 年 9 月 15 日(星期一)至 9 月 19 日(星期五)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 autobio@autobio.com.cn 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 郑州安图生物工程股份有限公司(以下简称"公司")已于 2025 年 8 月 22 日发布公司 2025 年半年度报告,为便于广大投资者更全面深入地了解公司 2025 年上半年度经营成果、财务状况,公司计划于 2025 年 9 月 22 日上午 9:00-10:00 举行 2025 年半年度业绩说明会,就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开,公司将针对 2025 年上半年度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通,在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 郑州安图生物工程股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大 ...